オシメルチニブメシル酸塩 価格

メーカー	製品番號	製品説明	CAS番號	包裝	価格	更新時間	購入

オシメルチニブメシル酸塩 化學特性,用途語,生産方法

効能

抗悪性腫瘍薬, 受容體チロシンキナーゼ阻害薬

商品名

タグリッソ (アストラゼネカ)

説明

Osimertinib is active against exon 19 deletions, exon 21 mutations, and also the exon 20 T790M mutations. It is preferentially selective for mutated EGFR, and therefore toxicity at therapeutic doses is lower than for first- and second-generation agents. Notably, osimertinib is able to cross the blood-brain barrier, making it active against disease in the CNS.

適応癥

The collection of ibrutinib (Imbruvica(R), Pharmacyclics Inc.), afatinib, and osimertinib represents the small, yet expanding, group of covalent SMKIs. Ibrutinib is a non-receptor Bruton’s tyrosine kinase inhibitor approved for the treatment of relapsed chronic lymphocytic leukemia. Afatinib, approved for NSCLC in 2013 and squamous NSCLC in 2016, is a second-generation irreversible EGFR inhibitor that targets wild-type EGFR, the mutant T790M EGFR, and HER2. Osimertinib (AZD9291), which was approved by FDA in November 2015, is a third-generation irreversible EGFR inhibitor that selectively targets the mutant T790M EGFR. Rociletinib, which shares a high degree of structural similarity with that of osimertinib, is a promising covalent EGFR inhibitor developed by Clovis Oncology aimed for the treatment of patients with EGFR T790M-mutated NSCLC, until the company terminated its development in May 2016 following a negative vote fromthe FDA’sOncologic Drugs Advisory Committee.

定義

ChEBI: A methanesulfonate (mesylate) salt prepared from equimolar amounts of osimertinib and methanesulfonic acid. Used for treatment of EGFR T790M mutation positive non-small cell lung cancer.

主な応用

Osimertinib mesylate is approved to treat: Non-small cell lung cancer that has certain EGFR gene mutations. It is used in adults: As adjuvant therapy after surgery to remove the cancer; As the first therapy for cancer that has spread to other parts of the body, or in patients whose cancer has spread to other parts of the body and got worse during or after treatment with another EGFR tyrosine kinase inhibitor.

brand name

Tagrisso^TM

副作用

Osimertinib toxicity is dose-dependent and is associated with fewer gastrointestinal and dermatologic adverse events than with other approved EGFR TKIs.

オシメルチニブメシル酸塩 上流と下流の製品情報

原材料

準備製品

オシメルチニブメシル酸塩 生産企業(yè)

名前	電話番號	電子メール	國籍	製品カタログ	優(yōu)位度
Zison Pharmaceutical (Shandong) Co., Ltd.	+86-0086-531-88259693 +86-18660188356	tracy.li@zisonpharm.com	China	57	58
SHANDONG BOYUAN PHARMACEUTICAL CO., LTD.	+86-0531-69954981 +8615666777973	dwyane.wang@boyuanpharm.com	China	211	58
Hebei Chuanghai Biotechnology Co,.LTD	+86-13131129325	sales1@chuanghaibio.com	China	5893	58
Henan Bao Enluo International TradeCo.，LTD	+86-17331933971 +86-17331933971	deasea125996@gmail.com	China	2472	58
Shaanxi Haibo Biotechnology Co., Ltd	+undefined18602966907	qinhe02@xaltbio.com	China	997	58
Henan Fengda Chemical Co., Ltd	+86-371-86557731 +86-13613820652	info@fdachem.com	China	20288	58
Apeloa production Co.,Limited	+8619933239880	admin@apcl.com.cn	China	852	58
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.	+86-18600796368 +86-18600796368	sales@sjar-tech.com	China	375	58
S&Y Biochem Co.,Ltd	+8617774091612	marketing@sybiochem.com	China	126	58
Capot Chemical Co.,Ltd.	+86-（0）57185586718 +86-13336195806	sales@capot.com	China	29791	60

1421373-66-1(オシメルチニブメシル酸塩)キーワード:

---

• 1421373-66-1
• AZD-9291 (Mesylate)
• AZD-9291 mesylate N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide methanesulfonate (1:1)
• Osimertinib Mesylate(AZD9291)
• Osimertinib mesylate
• Mereletinib Ms salt
• AZD9291 Ms salt, Osimertinib Ms salt
• N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide methanesulfonate
• AZD-9291 MESYLATE(OSIMERTINIB)
• N-(2-(N-(2-(dimethylamino)ethyl)-N-methylamino)-4-methoxy-5-((4-(1-methyl-1H-indole-3-yl)pyrimidine-2-yl)amino)phenyl)acrylamide methanesulfonate
• Mereletinib mesylate, 98%, a potent and selective mutated forms EGFR inhibitor
• AZD-9291 (MESYLATE);TAGRISSO;OSIMERTINIB MESYLATE
• AZD-9291 mesylate (Osimertinib mesylate
• AZD-9291 mesylate (Osimertinib,Mereletinib)
• MERELETINIB MESYLATE; EGFR INHIBITOR; AZD9291 MESYLATE; AZD 9291 MESYLATE;TAGRISSO
• Mesylate-AZD9291
• Osimertinib Mesylate (Tagrisso, Mereletinib, AZD-9291)
• N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide methanesulfonate(AZD9291 mesylate)
• Osimertinib Impurity 30
• Mereletinib mesylateQ: What is Mereletinib mesylate Q: What is the CAS Number of Mereletinib mesylate Q: What is the storage condition of Mereletinib mesylate Q: What are the applications of Mereletinib mesylate
• Mereletinib mesylate
• N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide methanesulfonate
• N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide methanesulfonate (1:1)
• Osimertinib
• Tagrisso
• N-[2-(2-dimethylaminoethylmethylamino)-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide mesylate salt
• Osimertinib d6
• Osimertinib methanesulfonate
• Osimertinib (AZD9291) mesylate
• Undecanoicacid,15-hydroxy-
• 2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1)
• オシメルチニブメシル酸塩
• オシメルチニブメシル酸塩 (JAN)